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Abstract
Surfactant Protein D (SP-D) is an oligomerized C-type lectin molecule with immunomodulatory properties and involvement
in lung surfactant homeostasis in the respiratory tract. SP-D binds to the enveloped viruses, influenza A virus and respiratory
syncytial virus and inhibits their replication in vitro and in vivo. SP-D has been shown to bind to HIV via the HIV envelope
protein gp120 and inhibit infectivity in vitro. Here we show that SP-D binds to different strains of HIV (BaL and IIIB) and the
binding occurs at both pH 7.4 and 5.0 resembling physiological relevant pH values found in the body and the female
urogenital tract, respectively. The binding of SP-D to HIV particles and gp120 was inhibited by the presence of several
hexoses with mannose found to be the strongest inhibitor. Competition studies showed that soluble CD4 and CVN did not
interfere with the interaction between SP-D and gp120. However, soluble recombinant DC-SIGN was shown to inhibit the
binding between SP-D and gp120. SP-D agglutinated HIV and gp120 in a calcium dependent manner. SP-D inhibited the
infectivity of HIV strains at both pH values of 7.4 and 5.0 in a concentration dependent manner. The inhibition of the
infectivity was abolished by the presence of mannose. SP-D enhanced the binding of HIV to immature monocyte derived
dendritic cells (iMDDCs) and was also found to enhance HIV capture and transfer to the T-cell like line PM1. These results
suggest that SP-D can bind to and inhibit direct infection of T-cells by HIV but also enhance the transfer of infectious HIV
particles from DCs to T-cells in vivo.
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Introduction
Surfactant protein D (SP-D) is a secreted soluble C-type lectin
with a collagenous domain belonging to the group termed
collectins [1]. Collectins are comprised of structural units
composed of three polypeptide chains. Each chain has four
domains: 1) a N-terminal region with cysteine residues involved in
the higher oligomerisation of the mature SP-D molecule; 2) a
collagen like region with hydroxylated lysine and proline residues;
3) an a-helical coiled-coil neck region where the initial trimeric
unit formation is initiated and 4) a calcium-dependent carbohy-
drate recognition domain (CRD) at the C-terminus that is
conserved across species [2]. The mature SP-D protein is
oligomerized into a dodecameric molecule with four trimeric
units that come together involving the N-terminal region with two
cysteine residues in each poly peptidechain [3,4]. This collectin
family includes other members such as surfactant protein A (SP-A)
and mannose binding lectin (MBL). The affinity of a single CRD
towards a single carbohydrate epitope found of the surface of a
pathogenic microorganism is low. However, through the forma-
tion of the trimeric unit and the additional higher order
oligmerization of the mature molecule, collectins have a high
avidity for repeated carbohydrate structures as seen on micro
organisms. SP-D promotes agglutination and phagocytosis of
micro organisms [5,6], has a chemotactic effect on phagocytes
[7,8], modulates inflammatory responses [6,9,10], has a direct
anti-microbial effect [11,12] and has been shown in in vivo models
to be involved in the response to and clearance of viruses such as
influenza A virus (IAV) and respiratory syncytial virus (RSV) [13–
15].
Human immunodeficiency virus (HIV) is the causative agent of
Acquired Immune Deficiency Syndrome (AIDS). According to the
World Health Organisation (WHO) 34 million people were living
with HIV, 2.7 million people were newly infected and 1.8 million
died of AIDS in 2010 [16]. The envelope protein (Env) is a trimer
made of three copies of each glycoprotein 120 (gp120) and
glycoprotein 41 (gp41). Both proteins play crucial roles in the entry
process of the virus into cells by mediating the fusion between viral
and cellular membranes during the entry process (recently
reviewed by Caffrey) [17]. Gp120 is highly glycosylated with
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glycans [18]. This makes a ‘‘glycan shield’’ that masks HIV from
host immune recognition [19], contributes to correct folding of the
protein and helps virions bind to the host cell surface [20].
SP-D was originally isolated from lung surfactant but has been
shown to be expressed on all mucosal surfaces including
gastrointestinal and female genitourinary tracts [21–23]. SP-D
can be isolated from various body fluids including amniotic fluid,
bronchoalveolar lavage (BAL), saliva and tear fluid [22,24,25].
Direct interaction between MBL and HIV has been shown by
several groups [26,27] and we have recently shown that SP-A
binds to HIV and inhibits infection of CD4+ cells but enhances
dendritic cell-mediated viral transfer to CD4+ cells [28]. SP-D has
also been shown to interact with HIV - specifically gp120 - and the
interaction was dependent on the degree of glycosylation of gp120
[29]. Furthermore, SP-D was found to inhibit HIV infection of the
U937 monocyte-like cell line [29]. Here we show that SP-D binds
to several strains of inactivated HIV particles and SP-D specifically
interacts with gp120 at both pH 7.4 and pH 5.0. The SP-D -
gp120 interaction was investigated using ELISA assays and surface
plasmon resonance. The interaction was further characterized
using inhibition assays with different hexoses and the epitope that
SP-D interacts with on gp120 was mapped using three gp120
binding proteins. SP-D agglutinates HIV particles and gp120
molecules in the presence of calcium and the addition of EDTA
dissociated the agglutinated complexes. SP-D enhanced the
binding of HIV to immature monocyte derived dendritic cells
(iMDDCs). SP-D also enhanced the transfer of HIV from
iMDDCs to CD4+ T-cells at pH values of 7.4 and 5.0. Thus,
SP-D appears to be a dual modulator of HIV infection by
protecting CD4+ T-cells from direct infection but enhancing the
transfer of HIV from DCs to CD4+ T-cells.
Materials and Methods
Ethics Statement
Human bronchoalveolar lavage (BAL) was obtained from
patients diagnosed with pulmonary alveolar proteinosis undergo-
ing this procedure for therapeutic purposes. The procedure was
approved by the London National Health Service Research Ethics
Committee and BAL was donated by informed patients with
written consent. Blood was donated by informed male participants
(ages: 18–40 years) with written consent and the procedure was
approved by the University Research Ethics Committee at
University of Oxford.
Human immunodeficiency virus and T cell lines
Aldrithiol-2 (AT-2) inactivated HIV BaL particles were
provided by Mr. Julian Bess of the National Cancer Institute
AIDS Vaccine Program (SAIC,Frederick, MD). Infectious HIV
BaL (ARP118) and HIV IIIB (ARP101.1) were obtained from the
National Institute of Biological Standards and Control (NIBSC)
AIDS Reagent program. High titer stocks were generated by
infecting 1610
7 pelleted PM1 cells for 90 min at 37 uC/5% CO2
with 500 mL of viral supernatant. After incubation, 10 mLs of
RPMI 1640 supplemented with 50 U/ml penicillin/streptomycin
(Life Technologies), 2 mM L-Glutamine (Sigma-Aldrich), and
10% (v/v) foetal bovine serum (FBS) (Sigma-Aldrich) (R10) was
added and the virally infected cell culture was transferred to a T25
flask for growth. Aliquots (1 mL) were taken on days 5 and 7 and
assayed for Reverse Transcriptase activity using the SPA Quant-
T-RT assay kit (Amersham) according to the manufacturer’s
instructions.
The PM1 (ARP057) cell line and the C8166 (ARP013) cell line
were obtained from the NIBSC AIDS Reagent Program. PM1 is a
sub clone of the neoplastic T-cell line Hut78 [30] and C8166 is an
immortalized human umbilical cord blood lymphocyte cell line
developed by cocultivation or fusion of fresh cells with T cells
cultured from leukemia-lymphoma patients containing human T-
cell leukemia-lymphoma virus [31].The cells were grown in R10
and split routinely 1:8 to maintain the cells in the exponential
growth phase. Cells were routinely tested for mycoplasma
infection.
Proteins
SP-D was purified by sugar-affinity chromatography from
therapeutic bronchoalveolar lavage (BAL) obtained from patients
diagnosed with pulmonary alveolar proteinosis as described
previously [32]. MBL was purified from a pool of serum as
described previously [27,33]. Recombinant soluble DC-SIGN was
produced as described previously [34]. The concentration of SP-
D, MBL or DC-SIGN was determined by analysis of amino acid
composition. Recombinant gp120 IIIB produced in Chinese
hamster ovary (CHO) cells, biotinylated gp120 IIIB, and FITC-
labeled gp120 IIIB were purchased from Immunodiagnostics.
Cyanovirin (CVN) and polyclonal rabbit anti-CVN Ab were
provided by Dr. Kirk Gustafson (National Cancer Institute,
Frederick, MD). SP-D and MBL used in all cell-based assays were
treated for endotoxin removal, by passing the protein solutions
through a 10 mL Polymyxin B column (Detoxi-Gel; Pierce) in
sterile PBS (pH 7.4). Remaining levels of endotoxin were assayed
using a Limulus Amoebocyte Lysate kit, according to the
manufacturer’s instructions (Bio-Whittaker). An endotoxin level
of ,10 pg/mg of protein was judged acceptable for use in cell-
based assays.
Enzyme Linked Immunsorbent Assays (ELISAs)
Inactivated HIV BaL (10 mg/mL), gp120 IIIB (2 mg/mL), SP-D
or MBL (2 mg/mL) was immobilized on 96-well plates (Nunc,
Maxisorp) in 0.1 M sodium bicarbonate buffer (pH 9.6) at 4 uC for
18 h. The wells were washed with PBS and 0.05% (v/v) Tween 20
(PBST) and blocked in 3% (v/v) BSA for 2 h at 37 uC.
Immobilization of virus was verified by incubation with a purified
pooled anti-HIV Env IgG (kindly provide by Dr Quentin
Sattentau (Dunn School of Pathology, Oxford University, Oxford,
UK)), followed by peroxidase conjugated anti-human IgG, and
detection using the H2O2-tetramethylbenzidine-based (H2O2-
TMB) chromogenic substrate according to the manufacturer’s
instructions (Bio-Rad). After washing away excess BSA with
PBST, the wells were incubated with increasing concentrations of
SP-D (0–4 mg/mL) or AT-2 inactivated HIV BaL (0–10 mg/mL)
in Tris buffered saline with calcium (TBSC: 20 mM Tris-HCl,
150 mM NaCl, 5 mM CaCl2, pH 7.4) with 25% (v/v) human
serum or Tris buffered saline with EDTA (TBSE; 20 mM Tris-
HCl, 150 mM NaCl, 2 mM EDTA, pH 7.4) with 25% (v/v)
human serum. For binding experiments performed at a pH of 5.0,
SP-D or AT-2 inactivated HIV BaL was incubated in 20 mM
Sodium Acetate, 150 mM NaCl, 25% (v/v) human serum and
either 5 mM CaCl2 or 2 mM EDTA. The wells were washed in
the corresponding binding buffer, and incubated with biotinylated
anti-human SP-D Ab against recombinant fragment of SP-D
(1 mg/mL) at 37 uC for 2 h. Bound HIV particles were lysed in
PBS with 1% (v/v) Triton X-100 and p24 Ag was measured by
ELISA according to the manufacturer’s instructions (Immuno-
diagnostics). The collectin-antibody complexes or p24 Ag were
detected using HRP-streptavidin and H2O2-TMB. The absor-
SP-D and HIV
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photomer (Multiscan Ascent, Labsystems; Fisher).
Dot Blot Assay
Purified human SP-D (100 ng), and recombinant gp120 (200 ng
and 2-fold serial dilutions) were carefully dotted onto Hybond-C
Extra nitrocellulose membrane discs (Amersham Biosciences) and
allowed to dry in a Petri dish. Membranes were incubated with 2%
(w/v) BSA in PBST for 2 h at room temperature. Membranes
were washed three times with either 20 mL of TBSC or TBSE.
Membranes were then incubated with 10 mL of TBSC or TBSE
with SP-D (200 ng/mL) for 1 h. The membranes were washed as
above, and incubated further with 10 mL of biotinylated rabbit
polyclonal anti-human SP-D for 1 h. This antibody has previously
been used for detection of SP-D [35,36]. Unbound antibody was
washed away as described above, and the membranes were
incubated with HRP-streptavidin (1:200) for 20 min. SP-D
complexes were detected by ECL reagents (Amersham Bioscienc-
es).
Surface Plasmon Resonance
SP-D (1 mg/mL) was immobilized on a flow cell at the
approximate reading of 1000 resonance units, on a SA chip in a
pH 5.0 Sodium Acetate buffer according to the manufacturer’s
instructions (Biacore). To determine whether HIV could bind to
the immobilized SP-D, AT-2 inactivated HIV BaL particles
(100 mg/mL) were passed over the cell in 10 mM HEPES (pH
7.4), 150 mM NaCl, 5 mM CaCl2, 0.005% (v/v) surfactant P-20,
0.02% (w/v) NaN3 (HSC) buffer or 10 mM HEPES (pH 7.4),
150 mM NaCl, 1 mM EDTA, 0.005% (v/v) surfactant P-20,
0.02% (w/v) NaN3 (HSE) at 10 mL/min for 2 min at 25 uC. The
complexes were allowed to disassociate for 90 sec, and bound viral
particles were removed with two 20 mL washes of HSE and the
chip was re-equilibrated with 20 mL of HSC buffer. Competition
assays using the SP-D chip were accomplished by flowing AT-2
inactivated HIV particles (100 mg/mL) in the presence of different
concentrations of hexoses (maltose, mannose, GlcNac, galactose;
0–500 mM). The surface plasmon resonance response obtained in
the absence of any competitor was considered as 100%, and the
relative binding was calculated for each competitor concentration.
To examine the effects of pH on the binding of HIV to
immobilized SP-D, AT-2 inactivated HIV BaL particles
(100 mg/mL) were diluted into a 50 mM Sodium Acetate,
50 mM Bis-Tris, 50 mM Tris, 150 mM NaCl, 5 mM CaCl2
buffer (Buffering capacity: pH 4.5–8.0) at various pHs (5.0, 5.5,
6.0, 6.5, 7.4). AT-2 inactivated HIV BaL particles (100 mg/mL)
were passed over the flow cell in HSC at a particular pH at
10 mL/min for 2 min at 25 uC. The complexes were allowed to
disassociate for 90 sec and bound viral particles were removed
with two 20 mL washes of HSE and the chip was re-equilibrated
with 20 mL of HSC buffer.
Association and dissociation rate constants of SP-D at various
pHs were calculated by nonlinear fitting of the primary sensogram
data using the BIAevaluation 2.0 software (Pharmacia Biosensor)
and the method described by MacKenzie et al [37]. Relative
affinity was calculated using these rate constants.
Agglutination Assay
Agglutination assays were performed as described previously
[38] by measuring the change in protein absorbance at 400 nm in
a Cecil CE 292 spectrophotometer. Absorbance at 400 nm of
20 mM Tris-HCl (pH 7.4), 150 mM NaCl was stabilized for
3 min at 23 uC, at which SP-D (10 mg/mL), HIV MN (10 mg/
mL), or gp120 IIIB (10 mg/mL) was added. After an additional
equilibration for 3 min, CaCl2 (10 mM) was added to the sample
cuvette and the absorbance was monitored at 30 sec intervals over
10 min. Reversal of virus and protein aggregation was achieved by
addition of EDTA (10 mM) and absorbance at 400 nm was
recorded for an additional 2 min.
HIV infectivity assay
PM1 cells for HIV BaL and C8166 cells for HIV IIIB were
infected with 3–log10 TCID50/mL of virus inoculum (HIV BaL
or IIIB) that had been pre-incubated with 10 mL of serially diluted
SP-D (final concentration: 1–10 mg/mL) for 1 h at 37 uC. 90 min
post infection, the cells were washed extensively, resuspended in
fresh R10, and aliquoted into 200 mL volumes containing
5610
4 cells/well. Infected cells were then incubated for 4–5 days
before measuring extracellular p24 content from culture superna-
tants by ELISA (Immunodiagnostics).
Competition assays
SP-D (0–40 mg/mL) was incubated simultaneously with the
protein competitors recombinant soluble DC-SIGN, recombinant
CD4 (both biotinylated) or the small lectin cyanovirin (CVN) in
wells coated with recombinant gp120 IIIB (2 mg/mL). Bound
biotinylated CD4 and DC-SIGN was detected by streptavidin-
HRP incubation for 30 min at 37 uC, followed by H2O2-TMB.
Generation and characterization of primary dendritic
cells
Immature monocyte-derived DCs (iMDDCs) were generated
from a highly enriched population of CD14 monocytes. Peripheral
blood mononuclear cells (PBMCs) were isolated from blood
obtained from healthy male donors (ages: 18–40) using a Ficoll-
Hypaque density gradient (Amersham Biosciences). PBMCs were
washed thoroughly with sterile PBS and contaminating red blood
cells were lysed using ACK lysis buffer. PBMCs were labeled with
anti-CD14 microbeads (Miltenyi Biotec) and CD14 cells were
isolated using the AutoMACS (Miltenyi Biotec) magnetic cell
sorter. The purity of the isolated CD14 cells was .95% as assessed
by flow cytometry. iMDDCs were cultured from monocytes in the
presence of IL-4 (500 U/mL; R&D Systems) and GM-CSF
(800 U/mL; R&D Systems), with fresh cytokines added on days 3
and 5. At day 7, the phenotype of the cultured iMDDCs was
confirmed by high CD11c and HLA-DR expression, and low
CD83 expression as determined by flow cytometry (supplementary
Figure S1).
DC-gp120 binding assay
FITC-labeled gp120 IIIB was incubated in the presence of SP-
D( 5mg/mL) in R10 made 5 mM CaCl2 for 1 h at 4 uC. SP-D-
gp120 complexes were incubated with iMDDCs (1610
5) and
incubated for 2 h at 4 uC to prevent uptake of gp120. Trypan blue
exclusion staining revealed more than 95% viability after
incubation with gp120 and SP-D. Cells were pelleted and washed
in PBS with calcium and magnesium and then fixed in 3%
paraformaldehyde for analysis by flow cytometry.
HIV uptake assay
AT-2 inactivated HIV BaL was incubated in the presence of SP-
D( 5 mg/mL) in R10 made 5 mM CaCl2 for 1 h at 37 uC.
Collectins complexed with HIV were then added to iMDDCs
(1610
5) aliquoted into wells of a 96-well tissue culture treated
microtiter plate and incubated for 2 h at 37 uC. Cells were
pelleted and extensively washed with RPMI and with PBS
containing 10 mM EDTA to remove externally bound HIV
SP-D and HIV
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lysed in PBS with 1% (v/v) Triton X-100 and viral uptake was
measured by p24 ELISA according to the manufacturer’s
instructions (Immunodiagnostics).
DC-mediated HIV transmission assay
DC-mediated HIV transmission assays were performed as
described previously (19). Infectious HIV BaL particles were
incubated in the presence of SP-D (1–10 mg/mL) for 1 h at 37 uC
before incubation with iMDDCs (1610
5) for 2 h at 37 uC. Cells
were extensively washed to remove unbound virus, and then
placed in a fresh 96-well plate for co-culture with PM1 cells
(1610
5/well). Culture supernatants were collected after 4–5 days
and virus replication was monitored by p24 ELISA.
Statistical analysis
Statistical comparisons were made using the unpaired t-test with
Welch’s correction and for more than two groups one way
ANOVA with one control group was used. Means, standard
derivations and values of p for the differences between means were
calculated using Excel software (Microsoft) or GraphPad Prism
(GraphPad Software) version 5. Values p,0.05 was considered
statistically significant.
Results
Binding of SP-D to HIV by ELISA and Surface Plasmon
Resonance
To determine whether SP-D can bind to HIV, we immobilized
a fixed amount (10 mg/mL) of AT-2 inactivated HIV BaL particles
in a microtiter plate. Inactivation with AT-2 has previously been
shown to have no effect on the conformational structure of HIV
particles in comparison to infectious virus [39]. Serial dilutions of
SP-D (0–4 mg/mL) were allowed to bind to the immobilized HIV
BaL particles and the bound collectin was detected using an anti-
SP-D (n/CRD) antibody. SP-D bound to immobilized BaL HIV
particles in the presence of CaCl2, but the binding was inhibited
by both mannose and EDTA, suggesting involvement of the C-
type lectin CRD (Figure 1A). Given our interest in examining the
role of SP-D in early phase HIV infection, we investigated whether
lowering the pH to the physiological buffering range of the vaginal
tract (approximately pH 5.0; [40]) could affect the binding of SP-D
to virus using the ELISA. Incubation of AT-2 inactivated HIV
BaL in microtiter wells coated with SP-D further verified the
interaction between the collectins and HIV. The binding was
studied at both a pH of 7.4 and 5.0 in order to replicate the
environments of the body’s blood pH value and the pH of the
female vaginal tract, respectively. Bound viral particles were lysed
in PBS with 1% (v/v) Triton X-100 and p24 antigen was
measured by ELISA. Immobilized SP-D binds to HIV BaL
particles at a pH of 7.4 in the presence of calcium, but is inhibited
by mannose and EDTA. At a pH of 5.0, binding of SP-D to
particles to immobilized SP-D was significant in the presence of
CaCl2, but was inhibited by mannose and EDTA (Figure 1B).
Similar results were obtained for the binding of SP-D to HIV MN
particles at a pH of 7.4 (not shown). To verify the interaction
between SP-D and HIV using another methodology, we further
investigated the nature of the SP-D binding to HIV by surface
plasmon resonance. SP-D was immobilized on a BIACore chip, as
we have previously described for SP-A [28]. The binding was
dependent on the presence of calcium as no binding was seen in
the presence of EDTA. Surface plasmon resonance analyses
confirmed the interaction between SP-D and HIV and also
revealed a relative difference in the affinity of SP-D that is pH-
dependent (Figure 1C). Association and dissociation constants
were calculated using the approach described by MacKenzie et al
[36]. Interestingly, while the dissociation constants of SP-D were
essentially unchanged by pH, the association constants were
notably different, with a calculated relative binding affinity of 1.68
at a pH of 7.4 normalised to the binding affinity at pH 5.0, which
we set to 1.0 (relative binding affinity at pH 6.5=1.37, pH
6.0=1.21, pH 5.5=1.08). The absolute affinity of SP-D for HIV
could not be calculated given that the molecule is a tetramer of
individual SP-D trimers, which is why we have calculated and
report only the relative affinities.
We then performed the binding assay at pH 7.4 in the presence
of increasing concentrations of hexoses (0–40 mM). D-mannose
was particularly effective at inhibiting the SP-D-HIV interaction
relative to the other hexoses (Figure 1D). Glucose also effectively
inhibited the interaction of both collectins to HIV in comparison
to GlcNAc and D-galactose (Figure 1D). These results further
support our ELISA results that SP-D binds to HIV through the C-
type lectin activity of the CRDs.
Binding of SP-D to the gp120 envelope protein of HIV
We have previously shown that SP-A interacts with gp120 [28].
To directly determine whether SP-D can bind to gp120, we
immobilized a fixed amount (2 mg/mL) of recombinant gp120
IIIB expressed in CHO cells on an ELISA plate. SP-D (0–1 mg/
mL) was allowed to bind to gp120 IIIB, and the bound protein was
detected by biotinylated anti-SP-D (n/CRD) antibody. The result
showed that SP-D binds to gp120 IIIB in a concentration- and
calcium- dependent manner (Figure 2A) similarly to the binding of
inactivated HIV BaL particles. The binding was further confirmed
by dot blot assays where SP-D showed a binding to immobilized
recombinant gp120 in the presence of calcium whereas no binding
was seen in the presence of EDTA (Figure 2B). To characterize the
binding between SP-D and gp120 in more detail we examined the
binding at pH 7.4 and pH 5.0. SP-D bound to gp120 at both pH
7.4 and 5.0 in the presence of calcium whereas no binding was
seen in the presence of EDTA (Figure 2C).
Sugar competition of SP-D binding to recombinant
gp120
To further characterize the interaction between gp120 and SP-
D with greater sensitivity, we examined the binding of SP-D to
biotinylated gp120 IIIB immobilized on a BIACore chip. The
surface plasmon resonance (SPR) showed that SP-D (0–5 mg/mL)
bound to gp120 in a concentration-dependent manner under
physiological salt conditions (Figure 3A). To investigate the nature
of SP-D binding to gp120 further, we allowed SP-D (5 mg/mL) to
bind to gp120 IIIB immobilized on a BIACore chip in the
presence of increasing concentrations of hexoses (0–40 mM).
BIACore assays behaved similarly to a conventional ELISA system
with maltose and D-mannose inhibiting the interaction between
SP-D and gp120 with relatively low values compared to N-acetyl
glucosamine (GlcNAc) and D-galactose (Figure 3B). These results
suggest that SP-D binds to gp120 through its carbohydrate
recognition domain, while the strong inhibition by D-mannose
suggests that the high mannose glycans on gp120 are potential
ligands for SP-D. To further explore the interaction between SP-D
and gp120, we allowed SP-D (5 mg/mL) to bind to immobilized
mannan on a BIACore chip in the presence of increasing
concentrations of gp120 (0–100 mg/mL) and this showed a
concentration dependent inhibition of the interaction (Figure 3C).
MBL has been reported to bind to HIV and gp120 [26,41] and we
wanted to compare the binding of SP-D to gp120 with the binding
of MBL to gp120. Inhibition of SP-D binding to mannan occurred
SP-D and HIV
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e59047at a significantly lower concentration of gp120 than for the serum
collectin MBL. 50% inhibition was achieved at a 5 mg/mL
concentration of gp120 for SP-D and at a 15 mg/mL concentra-
tion for MBL (Figure 3D).
Competition of gp120 binding proteins to gp120 and SP-
D
To further define the specific SP-D epitope on gp120, we
evaluated the effect of SP-D on the binding of several gp120
binding proteins to monomeric gp120 IIIB (Figure 4). A fixed
amount of recombinant monomeric gp120 was immobilized on an
ELISA plate as monomeric gp120 is found in concentrations of
12–92 ng/mL in HIV-1 infected serum [42]. Soluble biotinylated
CD4 or DC-SIGN were then allowed to compete for the binding
to gp120 in the presence of increasing concentration of SP-D (0–
40 mg/mL). We also chose to determine whether SP-D could
compete the binding of the neutralizing protein cyanovirin (CVN),
which binds to mannose-dependent epitopes on gp120 [43]. The
binding of sCD4 and CVN was not affected by the presence of SP-
D at all SP-D concentrations tested, indicating that the binding
sites for sCD4 and CVN do not overlap with SP-D (Figure 4). The
binding of sDC-SIGN was statistically significant (p,0.05)
inhibited at all SP-D concentrations tested with a maximum
inhibition of 80% at the highest SP-D concentration tested when
compared to no SP-D present indicating an overlap with the
binding site for SP-D (Figure 4).
SP-D agglutinates HIV and inhibits infectivity of PM1 cells
with HIV
One of the important clearing mechanisms of SP-D is thought
to be agglutination of virus which has been shown for influenza A
virus [44]. In order to see if SP-D was capable of agglutinating
HIV, SP-D was incubated together with virus and the turbidity
change at 400 nm over time was measured in the presence of
calcium and then later after the addition of EDTA. SP-D
agglutinated HIV BaL particles in the presence of calcium and
the agglutinated complexes disassociated by the addition of EDTA
(Figure 5A). SP-D or virus alone did not self-agglutinate in the
presence of calcium (Figure 5A). A similar effect was seen when
SP-D was incubated with gp120 from HIV IIIB in the presence of
calcium and the complexes would disassociate by the addition of
EDTA (Figure 5B).
As our studies showed that SP-D interacts with both HIV and
gp120 and agglutinates both HIV and gp120, we next asked
whether SP-D could inhibit HIV infectivity. Infectious strains of
HIV BaL and IIIB were incubated with increasing concentrations
of SP-D before incubating with PM1 or C8166 cells. Experiments
with HIV BaL were performed at both pH 7.4 and 5.0 as R5
strains, such as HIV BaL, are typically found in the early phase
Figure 1. SP-D binds to HIV. A: Binding of different concentrations of native SP-D to immobilized AT-2 inactivated HIV BaL (10 mg/mL). SP-D
specifically binds to HIV in the presence of 5 mM CaCl2 (N), but not in the presence of 250 mM mannose (m) or 1 mM EDTA (q). Each data point
represents the mean 6 S.D. (n=3). * shows statistical significant increase in the binding of SP-D to HIV in the presence of calcium compared to the
presence of mannose or EDTA (p ,0.05). B: Binding of inactivated HIV BaL (10 mg/mL) to immobilized SP-D (2 mg/mL) at pH 7.4 and 5.0, as estimated
by the release of p24 antigen by lysis of HIV particles. SP-D binds to HIV in the presence of 5 mM CaCl2 (white), but binding is reduced in the presence
of 250 mM mannose (striped) or 1 mM EDTA (black). Each data point represents the mean 6 S.D. (n=3). C: Surface plasmon resonance response
showing the binding of HIV BaL particles to immobilized SP-D at incremental pH values from pH 5.0 to 7.4. Competition of SP-D binding to
inactivated HIV by hexoses. D: Competition of HIV BaL particles (10 mg/mL) binding to immobilized SP-D by various hexoses. The IC50 values for SP-D
were as follows: mannose (1.5 mM).glucose (5.4 mM) ..GlcNAc (12.2 mM=D-galactose (12.2 mM). Dotted line shows IC50.
doi:10.1371/journal.pone.0059047.g001
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strain and is mainly found during late-phase infections) was only
performed at pH 7.4. The pH dependent incubation was
conducted during the initial incubation of HIV particles with
SP-D and then the SP-D-HIV complexes were incubated with
PM1 cells. All cells were washed post-infection and then
resuspended in pre-warmed medium at a pH 7.4. There was a
SP-D concentration dependent inhibition of HIV BaL and at the
highest concentration of 10 mg/mL, SP-D inhibited infectivity of
HIV BaL to around 15% at pH 7.4 and 20% at pH 5.0
(Figure 5C). A similar SP-D concentration dependent infectivity
was seen for HIV IIIB particles at pH 7.4 where SP-D at the
highest concentration of 10 mg/mL tested reduced the infectivity
to 5% when compared to no SP-D present (Figure 5D). The effect
was reproducible with different preparations of SP-D and the
inhibitory effect of SP-D was completely abrogated when the pre-
incubation of SP-D with HIV particles was performed in the
presence of 100 mM D-mannose for both HIV BaL and IIIB
strains.
SP-D enhances the binding of gp120 to iMDDCs and
enhances viral uptake and transfer of HIV from iMDDCs
to CD4+ T cells
We have previously shown that SP-A enhances the binding of
gp120 to iMDDCs [28]. We were interested to know if SP-D had
the same effect on gp120 and iMDDCs and examined how SP-D
affected the interaction between gp120 and IMDDCs. FITC-
labeled gp120 (2 mg/mL) was incubated with iMDDCs in the
presence or absence of SP-D at both pH 7.4 and 5.0. Experiments
were performed at 4 uC to prevent internalization of gp120 by
iMDDCs. Based on the geometric mean fluorescence intensity
(GMFI) SP-D enhanced the association of FITC-labeled gp120 to
iMDDCs at pH 7.4 when compared to iMDDCs incubated with
only gp120 in the absence of SP-D (Figure 6A, p,0.05). However,
at pH 5.0 the increase seen in associated gp120 in the presence of
SP-D at pH 7.4 was much less and there was no statistical
difference between the association with gp120 and iMDDCs in the
presence or absence of SP-D (Figure 6A, p=0.409).
As several reports have shown that SP-D enhances the
phagocytosis of a number of microbial pathogens [5,15,45], we
investigated whether SP-D could enhance the uptake of HIV
particles by iMDDCs. AT-2 inactivated HIV BaL particles
(10 mg/mL) were incubated with iMDDCs in the presence and
absence of SP-D (5 mg/mL) at a pH of both 7.4 and 5.0 at 37 uC,
with modulation of the pH carried out in the same manner as the
gp120-DC binding experiment. After incubation, cells were
washed in 10 mM EDTA-containing buffer and then lysed and
analyzed for p24 antigen content. SP-D significantly enhanced the
uptake of particles by approximately 50% at a pH of 7.4 (p,0.05),
but although SP-D did increase the uptake of HIV at pH 5.0 this
was not statistically significant (Figure 6B). Thus, the results from
the uptake experiment corroborate the results from our gp120-
iMDDC binding experiment, and collectively suggest that SP-D
enhances the interaction and phagocytosis of HIV by DCs.
To investigate whether SP-D affects DC-mediated transfer of
HIV to CD4+ T cells, iMDDCs were incubated with infectious
HIV BaL particles in the presence and absence of SP-D (1-10 mg/
mL) at both a pH of 7.4 and a pH of 5.0. Modulation of the pH
was carried out in the same manner as the gp120-iMDDCs
binding and HIV uptake experiments. After the incubation,
iMDDCs were washed extensively and then co-cultured with PM1
cells for 5 days before analysis of culture supernatants by p24
ELISA. SP-D enhanced iMDDC-mediated transfer of HIV at a
pH of 7.4 in a dose-dependent manner, with an approximately 2-
Figure 2. SP-D binds to recombinant gp120. A: ELISA assay
showing the binding of different concentrations of native SP-D to
immobilized recombinant gp120 IIIB (2 mg/mL) made in CHO cells. SP-D
specifically binds to gp120 in the presence of 5 mM CaCl2 (N), but not
in the presence of 1 mM EDTA (q). Each data point represents the
mean 6 S.D. (n=3). * shows statistical significant increase in the
binding of SP-D to HIV in the presence of calcium compared to the
presence of mannose or EDTA (p ,0.05). B: Dot blots showing the
binding of SP-D to gp120. SP-D (100 ng) or the indicated amounts of
recombinant gp120 were dotted on a nitrocellulose membrane, and the
blots were incubated with SP-D (200 ng/mL) in either 5 mM CaCl2 or
1 mM EDTA. SP-D on the blot was detected by anti-SP-D (n/CRD)
antibody. The antibody detected the positive SP-D control in both SP-D
lanes. SP-D binds specifically to gp120 on the blots in a concentration-
dependent manner in the presence of calcium but not in the presence
of EDTA (gp120 lanes). C: Binding of gp120 IIIB (2 mg/mL) to
immobilized SP-D (2 mg/mL) at pH 7.4 and 5.0. SP-D bound to HIV in
the presence of 5 mM CaCl2 (white), but binding was reduced in the
presence of 1 mM EDTA (black). Each data point represents the mean 6
S.D. (n=3). * shows statistical significant increase in the binding of SP-D
to HIV in the presence of calcium compared to the presence of EDTA (p
,0.05).
doi:10.1371/journal.pone.0059047.g002
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SP-D concentration of 10 mg/mL tested (Figure 6C, p,0.05). SP-
D also enhanced the transfer of HIV at a pH of 5.0 by
approximately 50% relative to the DC control at the same pH and
this was also a statistically significant increase (Figure 6C, p,0.05).
Thus, these results suggest that while SP-D protects CD4+ cells
from direct infection, it may also have a harmful effect on the
body’s defence against HIV in both the lungs and the vaginal tract
via interactions with DCs.
Discussion
In this study, we investigated the interaction of SP-D with
several strains of HIV. We have previously shown that SP-A
interacts with HIV and enhances dendritic cell-mediated viral
transfer [28]. SP-D has also previously been shown to interact with
HIV and gp120 and inhibit HIV replication in in vitro cell culture
assays [29]. Therefore, we sought to characterize the interaction
between SP-D and HIV in more detail and to investigate whether
this interaction could have a significant effect on HIV pathogenesis
as found for SP-A.
Figure 3. Competition of SP-D binding to gp120 by hexoses. A: Surface plasmon resonance response showing the binding of SP-D to
biotinylated recombinant gp120 IIIB immobilized on a streptavidin chip. Each trace indicates the response units recorded at a given concentration of
SP-D (10, 5, 2.5, 1.25, and 0.625 mg/mL) in 5 mM CaCl2-containing (HSC) buffer (traces are in order of the highest to lowest concentration). B:
Competition of SP-D (5 mg/mL) binding to gp120 with hexoses. The effect of different concentrations of hexoses in competing with gp120 for SP-D
binding. The IC50 values were as follows: maltose; 6.5 mM.mannose; 7.8 mM..GlcNAc; 22.9 mM.D-galactose; 32.2 mM. Dotted line shows IC50. C:
Competition of SP-D binding to mannan with gp120. The effect of different concentrations of gp120 (0, 1.625, 3.125, 6.25, and 12.5 mg/mL) on the
binding of SP-D (5 mg/mL) to mannan was determined by the changes in the response units. An increase in the gp120 concentration results in a
decrease in the surface plasmon resonance response. D: Competition of gp120 binding for SP-D and MBL to mannan. Dotted line shows IC50
doi:10.1371/journal.pone.0059047.g003
Figure 4. Competition of gp120 binding to gp120 binding
proteins by SP-D. A fixed amount of recombinant gp120 IIIB (2 mg/
mL) was immobilized on an ELISA plate, and, soluble DC-SIGN (N)o r
soluble CD4 (&) was allowed to bind in the presence of the indicated
concentrations of SP-D (0–40 mg/mL). Absorbance (450 nm) in the
absence of competitor was considered as 100% binding. Each data
point represents the mean 6 S.D. (n=3).
doi:10.1371/journal.pone.0059047.g004
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AT-2 inactivated HIV particles in a calcium dependent manner
that is inhibitable by mannose and EDTA (Figure 1A). Infectious
HIV particles inactivated by AT-2 have previously been shown to
retain the conformational and functional integrity of the surface
proteins [39] indicating that SP-D would bind in a similar manner
to these particles. Furthermore, competition assays with different
hexoses using the surface plasmon resonance technique showed
that mannose had the lowest IC50 value (1.5 mM) followed by
glucose (5.4 mM) and then galactose and GlcNAc (both 12.2 mM)
(Figure 1B). The order of these saccharide selectivities is in the
same order as Crouch and colleagues previously have shown for
natural and full-length recombinant human SP-D [46]. The
requirement of calcium, the binding being inhibited by EDTA and
mannose, and the saccharide specificity in competition assays
suggests that binding of SP-D to HIV is mediated by the lectin
binding site in the CRD domain and that SP-D would interact
with a glycoconjugate on HIV. As one of the important ways of
viral transmission is via the female urogenital tract, which has a
pH value around 5, the interaction between SP-D and HIV was
investigated at both pH 5.0 and 7.4 (Figure 1B and 1C). This
showed that SP-D can bind to HIV at both pH values but that
binding at pH 5.0 results in a lower association constant and thus
relative affinity, when compared to interaction between SP-D and
HIV at pH 7.4. The binding profile of SP-D in the pH range from
7.4 to 5.0 is similar to what we have previously reported for SP-A
but in contrast to DC-SIGN, which loses its binding capacity to
HIV at pH 5.0 [28]. However, although SP-A showed an
increased binding to HIV at pH 5.0 when compared to pH 7.4 in
the presence of EDTA [28] no binding was seen to HIV with SP-
D in the presence of EDTA at both pH values indicating that the
interaction is a mainly a calcium dependent sugar-lectin interac-
tion. SP-D has previously been shown to interact calcium-
dependently with gp120 [29] and the interaction was dependent
on the presence of glycans on gp120 as no binding was observed to
de-glycosylated SP-D [28]. The results in this paper also showed a
calcium-dependent interaction between SP-D and gp120 and
furthermore, we show that the interaction occurred at both pH 7.4
and 5.0 (Figure 2) consistent with what we observed for whole
inactivated HIV particles (Figure 1). In order to further
characterize the interaction between SP-D and gp120 we
performed competition assays with saccharide hexoses. Maltose
Figure 5. SP-D agglutinates and inhibits infectivity of HIV. A: Kinetics of HIV particle agglutination by SP-D. SP-D (10 mg/mL) (%), HIV BaL
(10 mg/mL) (&), or SP-D and HIV BaL (N) were added at point (a) after initial equilibrium at 20 mM Tris-HCl, 150 mM NaCl. The turbidity change at
400 nm was monitored at 30 s intervals. After 3 min stabilization, 5 mM CaCl2 (final concentration) was added to the sample cuvette and turbidity
changes were measured again. Addition of EDTA (10 mM, final concentration) resulted in disassociation of SP-D induced aggregates. The same
experimental approach was used for B: SP-D (10 mg/mL) (%), gp120 IIIB (10 mg/mL) (&), or SP-D and gp120 (N). The results of a representative
experiment from three separate experiments for each assay are shown. C: Infectious HIV BaL particles were preincubated at a pH of 7.4 (black) or 5.0
(white) in the presence and absence of the indicated concentrations of SP-D (1–10 mg/mL) before inoculation with PM1 cells. The PM1 cells were
washed and day 5 culture supernatants were analyzed by p24 ELISA. Numbers in parenthesizes are the SP-D concentration in mg/mL and the
mannose concentration in mM. D: Infectious HIV IIIB particles at pH 7.4. Each data point represents the mean 6 S.D. (n=3). * shows statistically
significant decrease in p24 antigen in the presence of SP-D compared to no SP-D present(p,0.05). **shows statistically significant increase in p24
antigen in the presence of mannose relative to treatment with SP-D alone (p,0.05). Numbers in parenthesizes are the SP-D concentration in mg/mL
and the mannose concentration in mM.
doi:10.1371/journal.pone.0059047.g005
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followed by mannose (7.8 mM), GlcNac (22.9 mM) and D-
galactose (32.5 mM) (Figure 3B). The relative order of these
hexoses is in accordance with the IC50 values we found for
competition assays between SP-D and whole inactivated HIV
particles (Figure 1D) and what has been observed for whole SP-D
molecules and hexoses [46]. This was confirmed by the finding
that SP-D has a stronger affinity for gp120 than seen for MBL
(Figure 3D) which is in accordance with the report by Hartshorn
and colleagues showing that SP-D inhibited infectivity of HIV and
Figure 6. SP-D enhances binding of gp120 to iMDDC and enhances HIV capture and transfer by iMDDCs. Binding of FITC-labeled gp120
to iMDDCs in the presence and absence of SP-D (5 mg/mL) at A: pH of 7.4 or 5.0. DCs were incubated with FITC-labeled gp120, or FITC-gp120 and SP-
Da t4uC for 1 h and then washed extensively before analysis by flow cytometry. The iMDDCs were initially analysed in FACS dot plot showing size
(FSC-H) and granularity (SSC-H) characteristics. A gate (R1) was used to select for immature DCs and these were further analysed for binding of the
FITC labeled gp120 or FITC labeled gp120 in the presence of SP-D. A geometric mean fluorescence intensity (GMFI) was calculated for each histogram
plot and statistical analysis was performed using an unpaired t-test with Welch’s correction. * shows statistically significant increase in p24 antigen
uptake by DCs in the presence of SP-D compared to the uptake with no SP-D present (p ,0.05). N.s indicates no statistically significance between
gp120 and the presence of SP-D and no SP-D present (p=0.409). B: Virus captured by iMDDCs in the presence or absence of SP-D (5 mg/mL). DCs
were incubated with AT-2 inactivated HIV BaL particles for 2 h at 37 uC, washed extensively in 10 mM EDTA containing buffer, and lysed for analysis
by p24 ELISA. The value of virus captured by iMDDCs in the absence of SP-D at pH 7.4 was defined as 100%. Each bar represents the mean 6 S.D.
(n=3). *shows statistically significant increase in p24 antigen uptake by DCs in the presence of SP-D compared to no SP-D present (p ,0.05). C:
Infectious HIV BaL was incubated with iMDDCs in the presence or absence of the indicated concentrations of SP-D (0–10 mg/mL) at a pH of 7.4 or 5.0.
Unbound virus was removed by washing and iMDDCs were then co-cultured with PM1 cells for five days before levels of p24 antigen in the culture
supernatants was measured by ELISA. The value of virus transferred by iMDDCs to PMI cells in the absence of SP-D at pH 7.4 was defined as 100%.
*shows statistically significant increase in p24 antigen uptake by DCs in the presence of SP-D compared to no SP-D present (p ,0.05).
doi:10.1371/journal.pone.0059047.g006
SP-D and HIV
PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e59047influenza virus in vitro at significantly lower concentrations than
MBL [28,47].
To further characterize the interaction between SP-D and
gp120 we performed an ELISA based inhibition assay to test the
ability of SP-D to interfere with the binding of known ligands for
gp120. As shown in Figure 4, these proteins can be divided into
two groups: 1) CVN and sCD4 did not alter the SP-D binding
profile to immobilized gp120 and 2) DC-SIGN inhibited the
binding. Computer based modelling of a trimeric gp120 with
glycans [48] show a remarkable complementarity to the crystal
structure of a recombinant fragment of human SP-D [49]. These
molecules are not only complementary in terms of oligomerized
shape but also with electrostatic charge and the location of glycans
on gp120 and the carbohydrate binding sites in human SP-D
(Figure 7). However, the distance across the computer generated
oligomeric model of gp120 was estimated to be approximately 110
A ˚ from tip of a glycan to tip of another glycan across the
oligomerised molecule whereas the distance between the binding
sites in SP-D has been calculated to be 51 A ˚. This opens up the
possibility that SP-D could bind to the center of the oligomerized
gp120 molecule, by binding to glycans located in the V3 loop, and
thereby there would still be space for some of the other ligands
investigated here also targeting high mannose structures on gp120.
As the recombinant protein CVN neutralises HIV by targeting a
specific mannose-dependent epitope on gp120 [43] the observa-
tion here with the differential results shows that the SP-D and
CVN proteins probably target different epitopes on gp120. The
computer generated modelling of trimerized gp120 showed that
the CD4 binding site is predominantly located on the side of the
trimerized molecule and distant from the glycans which is
predominantly located on top of the trimerized molecule
(Figure 7). The competition assay showed that SP-D did not
affect the interaction of sCD4 with gp120. This result was
confirmed by immobilizing sCD4 and testing for binding to whole
inactivated HIV particles or gp120 in the presence of SP-D. Both
HIV and gp120 showed no change in the binding to sCD4 in the
presence of SP-D (data not shown). This confirms the suggestion
that SP-D binds to the glycans found on the top of the trimerized
gp120 molecule and therefore does not interfere with the CD4
binding site located on the side of the trimerized molecule. Given
that DC-SIGN has been shown to target the high mannose
oligosaccharides on gp120 [50], it was expected that SP-D would
compete this interaction. Only DC-SIGN was found to have
decreased binding to gp120 in the presence of SP-D indicating
that the epitopes on gp120 that SP-D and DC-SIGN bind to may
overlap. This decreased binding of DC-SIGN to gp120 in the
presence of SP-D was confirmed by immobilizing DC-SIGN and
testing for binding of whole inactivated HIV particles or gp120 in
the presence of SP-D. Both HIV and gp120 showed decreased
binding in the presence of SP-D (data not shown). These results
are different from our previous findings with SP-A, which inhibits
the binding of both sCD4 and DC-SIGN to gp120 [28]. As with
the result for CVN binding, these results indicate that SP-A and
SP-D bind to gp120 in different ways.
The concentration of SP-D in bronchoalveolar lavages from
healthy volunteers ranges from 100–900 ng/mL [51,52]. As SP-D
is diluted during the procedure of BAL the concentration of SP-D
in situ in the lung would be higher and our experiments performed
here are probably in that concentration range. SP-D was found to
agglutinate both gp120 and intact inactivated HIV BaL particles
in the presence of calcium (Figure 5). This is the first time that a
collectin has been shown to agglutinate HIV. SP-D was more
potent in agglutinating whole HIV particles than gp120 molecules,
which is not surprisingly given the size of HIV particles compared
to gp120 molecules and the number of gp120 molecules found on
each HIV particles. The ability of SP-D to agglutinate influenza A
virus has been shown to be an important factor for protection
against the virus [44] and we assume that a similar protective
function could be possible for SP-D and HIV. The agglutinating
function of SP-D towards HIV is not unique as we have also found
that SP-A was cable of agglutinating HIV particles under the same
experimental conditions (data now shown).
We have shown that SP-D inhibited infectivity of PM1 cells with
the R5 strain HIV BaL and C8166 cells with the X4 strain HIV
IIIB (Fig. 5). Assays with HIV BaL were performed at a pH value
of 7.4 and 5.0, representative of the overall body and the vaginal
tract, respectively, as R5 strains are typically found in early phase
infection [53]. Experiments with HIV IIIB were performed at a
pH of 7.4, as particles are found in the lungs during late-term
infection usually have a CXCR4 receptor tropism [53]. SP-D was
found cable of inhibiting both HIV strains to a degree of only 5–
10% infectivity at pH 7.4 for both HIV strains tested and to
approximately 20% at pH 5.0. Thus, these results indicate that SP-
D may have a significant effect in vivo by protecting CD4+ cells
from direct infection in a variety of physiological environments.
We show here that SP-D enhanced the association of FITC
labeled gp120 with iMDDCs at pH 7.4 (Figure 6A) indicating that
SP-D would facilitate the association between HIV and iMDDCs.
This was performed at 4 uC assuming that this would result in
association only and no active uptake would take place. In order to
be able to differentiate between association and uptake, these
results should be verified in the future using a quenching step and/
or confocal microscopy) fluorescence. That SP-D facilitated the
association between HIV and iMDDCs was seen when using HIV
BaL at both pH values of 7.4 and 5.0 (Figure 6C). The
enhancement of DC-mediated transfer of infection (Figure 6D)
suggests that SP-D would likely facilitate HIV infection through
this alternate viral dissemination pathway in vivo. The localization
of cells expressing SP-D in the gastrointestinal mucosa and the
female vaginal tract places the collectin at an important site to
affect virus interaction with DCs during early phase infection
[21,23], while the presence of SP-D in the respiratory tract would
facilitate the interaction of HIV with lung DCs. The mechanism of
SP-D-mediated enhancement of DC viral transfer that we
observed most likely involves the increase in gp120 binding and
viral uptake by DCs (Figures 5 and 6). Although iMDDCs are a
relatively good model for DC subsets involved in HIV infectivity in
vivo [54] and the levels of p24 Ag are considerably higher with the
use of PM1 cells as indicator cells in comparison to DCs alone
(data not shown), it is unclear how much viral transfer is
attributable to DC trans or cis-infectivity. Experiments with a
replication-defective, single cycle reporter HIV would allow for the
determination of whether viral replication is necessary for SP-D-
mediated enhancement of HIV transfer by DCs.
The decrease in DC-mediated transfer of infectivity as the pH is
reduced to 5.0 is likely the result of the loss of activity of HIV-
binding cell surface receptors, such as DC-SIGN [28], and
impaired HIV infectivity in an acidic environment [55]. The loss
of HIV binding by DC-SIGN as the pH was lowered to 5.0 is
consistent with previous reports which have shown that a drop in
pH results in a conformational change in the DC-SIGN CRD that
alters its binding capacity [56]. Our observation that SP-D is still
able to bind to HIV as the pH is lowered may therefore account
for the amplified effects by the collectin on gp120 binding and
HIV uptake at a pH of 5.0 (Figure 6). It is important to remember
that in an in vivo setting both SP-A and SP-D are present in the
lung and the vaginal mucosa and fluid [23,57] and any HIV
particles would probably be interacting with both collectins. This
SP-D and HIV
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and to be further enhanced by the interaction between collectins
and the SP-A and SP-D binding molecule DMBT1
gp-340 [58,59],
which is also present on mucosal surfaces and has also has been
shown to bind to HIV and gp120, inhibit infectivity in in vitro in
cells culture assay and facilitate trans-infection to T-cells [60–63],
or a number of other cellular candidate receptors for collectins,
such as SIRPalpha and calreticulin/CD91 [10].
In summary, this study is the first to establish an interaction
between SP-D and HIV at pH values of both 7.4 and 5.0. SP-D
also agglutinated HIV particles. Furthermore, our results suggest
that SP-D, as we have previously shown for SP-A, may be a dual
modulator of HIV infection by protecting CD4+ cells but
enhancing the transfer of infection by dendritic cells in vivo.
Therefore, we believe that our findings for the two collectins SP-A
and SP-D as HIV binding factors are important in advancing our
understanding of the innate immune response against HIV and
how this, in a future setting, could potentially be manipulated into
a therapeutic usage against HIV infections.
Supporting Information
Figure S1 Characterization of iMDDCs by flow cytom-
etry. The iMDDCs were initially analysed in FACS dot plot
showing size (FSC-H) and granularity (SSC-H) characteristics. A
gate (R1) was used to select for immature DCs and these were
further analysed for surface markers for cell type and differenti-
ation using FITC labeled antibodies for: CD11c, CD83 and MHC
II (HLA-DR). iMDDCs were positive for the DC-specific markers
CD11c and HLA-DR, but not for the mature marker CD83. The
dot plot and histograms are representative of the FACS screening
performed before iMDDCs were used for experimentation.
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Figure 7. Computer generated model of trimeric gp120 and human SP-D. A:C a worm representations of core gp120 (copper brown) and
the gp120 carbohydrate cores (blue), the (N-acetylglucosamine)2-(mannose)3cores shared by both high-mannose and complex N-linked glycan
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